Menu

Phacilitate Big Data In Precision Medicine 2016

1 - 2 November 2016 | Capital Hilton | WASHINGTON DC

Big Data in Precision Medicine 2016 Stats

Phacilitate Leaders Europe 2016

Agenda

DAY 1

Tuesday, November 1st 2016

Conference Day One: Tuesday November 1 2016

09:00 - 09:05
  • How the Precision Medicine Initiative is the ultimate big data project - and how we can overcome massive logistical barriers to achieve results
  • How the combination of transformative technologies in data analytics and decision-making processes has the potential to revolutionize the accessibility of information for precision medicine
09:05 - 09:25
  • Jerry Lee, PhDJerry Lee, PhDDeputy Director for Cancer Research and TechnologiesCancer Moonshot Task Force
09:25 - 09:45
  • Dr William DaltonCEO, M2Gen & DirectorThe DeBartolo Family Personalized Medicine Institute
09:45 - 10:05

Real-world data (RWD) is generally the term used to refer to any data which is collected outside of randomized clinical trials (RCT). The data can be from sources including patient data from hospitals and clinicians. The premise is that RWD combined with information from RCTs can provide better research outcomes and improved healthcare.

Unfortunately, available clinical trial information data is really not that big. It is also often dispersed and contradictory and includes duplicates through multiple entries that are not verified and/or matched. Many transformative actions with data are frequently heralded as a big data panacea long before any analytical conclusion can be applied.

This presentation will explore the challenges faced when approaching the question of clinical trial data merging and its interoperability with public clinical trial data for creating valuable insights for study placement.

10:05 - 10:25
  • Dr Anastasia ChristiansonDirectorate Head, Data Science and IT, Frederick National Lab for Cancer Research And SVPLeidos Biomedical Research
10:25 - 11:10
  • With more widely available health IT platforms to store and analyse vast amounts of electronic data from thousands of patients, how can be translate this information into actionable data for clinical research?
  • Integrating genotype and clinical phenotype data in the context of a drug development research strategy


Includes short presentation
Transforming Cancer Treatment: Integrating Data to Deliver on the Promise of Precision Medicine
Jonathan Hirsch, Founder and President, Syapse

Intelligent approaches to analysis in Big Data
 

11:50 - 11:55
11:55 - 12:10
  • How the transformative technologies in data analytics and decision-making processes has the potential to revolutionize the drug development process
  • The combination of structured and unstructured data presents a new opportunity to make accurate predictions of new targets based on all relevant information
  • Scott SpanglerScott SpanglerPrincipal Data ScientistWatson Health, IBM Almaden Research Center
12:10 - 12:20

Paradigm4 will present on creating a research environment based on 2800 complete patient records (ECG, clinical and outcomes) the Medical Information Mart for Intensive Care III (MIMIC III) - Re -MIMIC. Results from the application of signal processing and learning algorithms to identify patient cohorts will presented.

12:35 - 13:30
  • Scott SpanglerScott SpanglerPrincipal Data ScientistWatson Health, IBM Almaden Research Center
  • Dr Slava AkmaevChief Analytics OfficerBerg Health
  • Dr Wayne DanterCEOCritical Outcome Technologies
  • Dr Laura ElnitskiSenior Investigator, Translational and Functional Genomics Branch Head, Genomic Functional Analysis Section National Human Genome Research InstituteNIH

Clinical informatics applications - Clinical phenotype data: Promise & potential in drug development

11:50 - 11:55
11:55 - 12:15
  • Dr Michael GazianoMillion Veteran Programme Principal Investigator & PhysicianVA Boston Healthcare System
12:15 - 12:35
12:35 - 12:55
  • Methods to integrate clinical, molecular, and real world data at large scales to build tremendous cloud-based holistic models for simulation experiments and inquiries of disease, personalized patient care, and event prediction
  • Managing and deriving value from quantitative patient data to understand patient sub-populations, identify biomarkers of disease onset, progression, or patient stratification, assess clinical risk, and uncover mechanistic understanding of disease
  • Dr Diane WuestAssociate Director, Precision Medicine InitiativeGNS Healthcare
12:55 - 13:10
13:10 - 13:30
13:30 - 14:30

Bioinformatics application - Role of Big Data in identifying therapeutic targets and designing new drugs

14:30 - 14:35
  • Professor David SmithProfessor David SmithChairman of the Technology Assessment Group, Center for Individualized MedicineMayo Clinic
14:50 - 15:05
15:05 - 15:20

The central challenge in drug discovery is the alignment of the right drug applied to the right disease for the right segment of patients. A tremendous amount of research is being performed to address this issue, but the approaches and data produced are varied in quantity, quality and type, thus making it challenging to translate all of the knowledge to therapeutic applications. BioXcel has been pioneering the effort to apply machine learning and big data analytics to exploit the explosion of data and translating that into practical therapeutic applications. Examples of therapeutic leads identified and validated in immuno-oncology and neuroscience will be used as illustrative examples.

15:20 - 16:00
  • Using computational analytics experimental platforms to generate and translate information of disease mechanisms into actionable/validated drug targets
  • How is this to impact the traditional pharma development model? What are the implications on different therapeutic groups?
  • Professor David SmithProfessor David SmithChairman of the Technology Assessment Group, Center for Individualized MedicineMayo Clinic

Subgroups from Real World Evidence, applications in clinical development

14:30 - 14:35
14:35 - 14:55
  • Dr Glenn GerhardChair, Department of Medical Genetics and Molecular BiochemistryTemple University
14:55 - 15:15
15:15 - 16:00
  • Using patient-powered research that accelerates biomedical discoveries and provides clinicians with the knowledge to select the right treatments for the right patients at the right time
  • Integrating claims and real world clinical data into a product value proposition, as well as directing new research focuses
  • Dr Eric NeumannVP Knowledge InformaticsFoundation Medicine
  • Dr Hui CaoExecutive Director, CoE for RWE, Global Medical AffairsNovartis
  • Dr Josephine BriggsDirectorNational Center for Complementary and Integrative Health (NCCIH)
  • Shawn DolleyIndustry Leader, Health & SciencesCloudera

Big data in multi-omics analytics and biomarker discovery
 
 

16:30 - 16:35

Building a bridge between cutting edge science and the delivery of genomic medicine in clinical practice

16:35 - 16:55
17:35 - 18:00

Using clinical phenotype data sources to aid drug discovery, drug re-purposing and advancing clinical trials

16:30 - 16:35
16:35 - 16:50
17:05 - 17:20
18:00 - 19:30

Back to top of Day One

DAY 2

Wednesday, November 2nd 2016

Conference Day Two: Wednesday November 2 2016

Development of clinical data standard and interoperability to give us the ability to exchange data with meaning and actionable insights

09:00 - 09:05
09:25 - 09:45
  • Dr Sam ShekarDr Sam ShekarChief Medical Officer, Health DivisionNorthrop Grumman Information Systems
09:45 - 10:00
  • Dr Sean KhozinSenior Medical Officer, Office of Hematology and Oncology ProductsUS FDA
10:00 - 10:15
10:15 - 10:45
11:15 - 11:20
11:20 - 11:45
  • Working with stakeholders to harmonize efforts in data exchange through standardized processes
  • Dr Alex ShermanDr Alex ShermanDirector, Strategic Development & Systems, Neurological Clinical Research InstituteMassachusetts General Hospital
  • Dr Barbara BiererFaculty Co-Director, Multi-Regional Clinical Trials Center of Brigham and Woman's Hospital and Harvard (MRCT Center)Brigham And Woman's Hospital
  • Dr Dee AmanzeDr Dee AmanzeDirector of Clinical ConsultingSaama Technologies
  • Dr Elise BerlinerDirector of the Technology Assessment Program, Center for Evidence and Practice ImprovementAHRQ
11:45 - 12:00
  • Describe how ASCO's CancerLinQ has created a technology platform to bring big data insights to the point of care
  • Show how big data is being used to drive quality improvement in cancer care
  • Demonstrate how CancerLinQ supports discovery and innovation in precision medicine for researchers and life sciences
  • Dr Robert MillerDr Robert MillerSenior Director, Quality & Guidelines; Medical DirectorCancerLinQ, ASCO
12:00 - 12:30

Roundtable 1: How can you bring actionable data to clinical care to enable precision medicine?
Joseph Dudas, Division Chair, Enterprise Analytics, Mayo Clinic

Roundtable 2: How can actionable data drive precision medicine?
Dr Philip R.O. Payne, PhD, FACMI, Co-Founder, Signet Accel

Roundtable 3: Bridging the gap between Big Data and direct patient care
Dr. Dee Amanze, Director of Clinical Consulting, Saama Technologies

Roundtable 4: Putting Big Data to Work: Making Big Data Useful Across Large Organizations is Tablestakes for Therapeutics R&D
Bryan Spielman, Executive Vice President, Strategy, Seven Bridges

12:30 - 13:30

Creating a data-driven model for life science and healthcare

13:30 - 13:35
  • Dr Adam ResnickDirector of the Center for Data Driven Discovery in Biomedicine (D3b)Children's Hospital of Philadelphia
13:35 - 13:55
14:15 - 14:30
  • Understand the ground-breaking capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes
  • Johan BragHead of Imaging PhenomicsMedian Technologies

Re-evaluating the clinical trial paradigm using Big Data

13:30 - 13:40
  • Dr Alex ShermanDr Alex ShermanDirector, Strategic Development & Systems, Neurological Clinical Research InstituteMassachusetts General Hospital
13:40 - 14:00
14:00 - 14:30

Designing research platforms to service patient populations

15:00 - 15:15
  • Connections between the meaningful use of data and meaningful engagement of the individuals providing that data
  • Unity with people who have had their genomes sequenced to help make their data scientifically useful through sharing and collaborative interpretation
15:15 - 15:30
  • Sally OkunVP Advocacy, Policy & Patient SafetyPatientsLikeMe
15:30 - 16:00
  • The potential benefits of providing shared access to personal digital information are becoming evident throughout medical research - but how do you find an appropriate balance between the potential advantages to the research community and respecting individual's rights?

About Us

Phacilitate is a specialist in the organisation of exclusive events for leaders from the pharma and biotech communities. Our philosophy is simple - to deliver the ultimate in strategic knowledge exchange and networking through flawless, personalised service.

2016 Featured Speakers

  • jerry lee
    Jerry S.H. Lee, PhD
    Deputy Director for Cancer Research and Technologies
    Cancer Moonshot Task Force
  • Dr William Dalton, CEO, M2Gen, & Director, The DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
    Dr William Dalton
    CEO
    M2Gen, &
    Director, The DeBartolo Family Personalized Medicine Institute
    Moffitt Cancer Center
  • Dr Gary Palmer, CMO, President GPS Cancer Division, NantHealth
    Dr Gary Palmer
    CMO, President GPS Cancer Division
    NantHealth
  • Dr Slava Akmaev, Chief Analytics Officer, Berg Health
    Dr Slava Akmaev
    Chief Analytics Officer
    Berg Health
  • Dr Sandy Farmer, Executive Director, Enterprise Scientific & Technology Operations, Pfizer
    Dr Sandy Farmer
    Executive Director, Enterprise Scientific & Technology Operations
    Pfizer

Innovation Partner

MDCPartners, Innovation Partner at Phacilitate Big Data In Precision Medicine 2016

 

Gold Sponsors

  • Northrop Grumman, Gold Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Signet Accel, Gold Sponsor at Phacilitate Big Data In Precision Medicine 2016

 

Silver Sponsors

  • median
  • Molecular Health, Silver Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • OLink Proteomics, Silver Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Paradigm4, Silver Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Perthera, Silver Sponsor at Phacilitate Big Data In Precision Medicine 2016

 

Bronze Sponsors

  • CancerLinQ, Associate Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Cloudera, Bronze Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • gns healthcare at big data in precision medicine
  • Innoplexus, Associate Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Medial EarlySign, Bronze Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Saama, Bronze Sponsor at Phacilitate Big Data In Precision Medicine 2016
  • Seven Bridges, Roundtable Sponsor at Phacilitate Big Data In Precision Medicine 2016

 

2016 Attending Companies

  • Alexion
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxalta
  • Berg
  • BlueCross BlueShield Association
  • Bristol-Myers Squibb
  • Covance
  • Daiichi-Sankyo
  • Deloitte
  • Eli Lilly
  • European Commission
  • GE Healthcare Life Sciences
  • Geisinger
  • Genetech
  • Google Cloud Platform
  • H3 Biomedicine
  • Harvard Medical School
  • Humana
  • Intel
  • Janssen
  • Medtronic
  • Merck
  • National Institutes of Health
  • Novartis
  • Oracle
  • Otsuka
  • Parexel
  • Pfizer
  • Quintiles
  • Roche
  • Sanofi
  • Takeda
  • Teva
  • UCB